IMVT
Immunovant Inc (IMVT)
Healthcare • NASDAQ • $28.94+6.32%
- Symbol
- IMVT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $28.94
- Daily Change
- +6.32%
- Market Cap
- $5.89B
- Trailing P/E
- N/A
- Forward P/E
- -11.20
- 52W High
- $30.09
- 52W Low
- $13.52
- Analyst Target
- $40.29
- Dividend Yield
- N/A
- Beta
- 0.70
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Company websiteResearch IMVT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.